RICTOR and neoplasm: Importantly, Rictor knockdown increased paclitaxel- and doxorubicin-mediated growth inhibition and caspase 3/7 activation in a synergistic manner (Supplementary Fig. S5), consistent with the hypothesis that mTORC2 inhibition may amplify chemotherapy-induced tumor cell killing in TNBC cells.